5,5-三氟甲基异唑-3-噻吩-2-磺酰氯 | 229956-98-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5,5-三氟甲基异唑-3-噻吩-2-磺酰氯
• 英文名称: 5-(5-(trifluoromethyl)isoxazol-3-yl)thiophene-2-sulfonyl chloride
• 英文别名: 5-[5-(trifluoromethyl)isoxazol-3-yl]thiophene-2-sulfonyl chloride；5-(5-trifluoromethyl-isoxazol-3-yl)-thiophene-2-sulfonyl chloride；5-[5-(trifluoromethyl)-3-isoxazolyl]-2-thiophenesulfonyl chloride；5-[5-(trifluoromethyl)-1,2-oxazol-3-yl]thiophene-2-sulfonyl chloride
• CAS: 229956-98-3
• 化学式: C₈H₃ClF₃NO₃S₂
• mdl: MFCD00831001
• 分子量: 317.697
• InChiKey: TWGONVLMWWEOFL-UHFFFAOYSA-N

物化性质

• 熔点：
  108-111°C
• 沸点：
  425.1±45.0 °C(Predicted)
• 密度：
  1.668±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  96.8
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• 危险等级：
  IRRITANT, CORROSIVE
• 危险品标志：
  Xi,C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 危险品运输编号：
  UN 3261
• 储存条件：
  室温密封保存，并保持干燥。

SDS

Name:	5-[5-(Trifluoromethyl)isoxazol-3-yl]thiophene-2-sulfonyl chloride Material Safety Data Sheet
Synonym:
CAS:	229956-98-3

Section 1 - Chemical Product MSDS Name:5-[5-(Trifluoromethyl)isoxazol-3-yl]thiophene-2-sulfonyl chloride Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
229956-98-3	5-[5-(Trifluoromethyl)isoxazol-3-yl]th	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 229956-98-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pink
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 108 - 111 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H3ClF3NO3S2
Molecular Weight: 318

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, reducing agents, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen fluoride gas, fluorine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 229956-98-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-[5-(Trifluoromethyl)isoxazol-3-yl]thiophene-2-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 229956-98-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 229956-98-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 229956-98-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5,5-三氟甲基异唑-3-噻吩-2-磺酰氯 在 碘 、 chloroamine-T 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 21.5h， 生成 3-(5-((2-(iodomethyl)aziridin-1-yl)sulfonyl)thiophen-2-yl)-5-(trifluoromethyl)isoxazole
  参考文献：
  名称：

  N,C-双官能化双环[1.1.1]戊烷的双重自由基合成

  摘要：

  双环[1.1.1] pentylamines（BCPAs）是重要性日益增加，以制药业作为藻3个苯胺和富含的bioisosters ñ -叔丁基的基团。在这里，我们报告了使用双重自由基功能化策略轻松合成 1,3-二取代 BCPA。磺胺基自由基，通过 α-碘氮丙啶的碎裂产生，经过初始添加到 [1.1.1] 丙烷中，得到碘-BCPA；然后通过甲硅烷基介导的 Giese 反应将这些产物中新形成的 C-I 键功能化。这种化学反应也可以顺利转化为 1,3-二取代碘-BCP。可容纳多种自由基受体和碘-BCPA，可直接获取一系列有价值的类苯胺等排体。

  DOI：

  10.1021/jacs.1c04180
• 作为产物：
  描述：

  3-(2-噻吩基)-5-(三氟甲基)异唑 在 磺酰氯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 5,5-三氟甲基异唑-3-噻吩-2-磺酰氯
  参考文献：
  名称：

  [EN] HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE
  [FR] ANTAGONISTES DE LA VOIE HEDGEHOG ET MÉTHODES D'UTILISATION AFFÉRENTES

  摘要：

  公开号：

  WO2010141680A3

文献信息

• Visible-Light-Mediated Annulation of Electron-Rich Alkenes and Nitrogen-Centered Radicals from <i>N</i>-Sulfonylallylamines: Construction of Chloromethylated Pyrrolidine Derivatives
  作者：Lorène N. S. Crespin、Andreas Greb、David C. Blakemore、Steven V. Ley

  DOI：10.1021/acs.joc.7b02146

  日期：2017.12.15

  A visible-light-mediated annulation of N-sulfonylallylamines and olefins is reported. Rapid access to highly functionalized chloromethylated pyrrolidines can be achieved using mild conditions for the generation of nitrogen-centered radicals. Both a transition-metal-based catalyst and an organic dye can be used as photosensitizers with 0.5 mol % loading. The reaction was found to be applicable to a

  报道了N-磺酰基烯丙基胺和烯烃的可见光介导的环化。使用温和条件生成氮中心自由基可以快速获得高度官能化的氯甲基化吡咯烷。过渡金属基催化剂和有机染料都可以用作具有0.5 mol％负载量的光敏剂。发现该反应适用于多种富电子和电子中性的烯烃。
• A Visible‐Light‐Mediated Radical Smiles Rearrangement and its Application to the Synthesis of a Difluoro‐Substituted Spirocyclic ORL‐1 Antagonist
  作者：James J. Douglas、Haley Albright、Martin J. Sevrin、Kevin P. Cole、Corey R. J. Stephenson

  DOI：10.1002/anie.201507369

  日期：2015.12

  systems, representing a new disconnection for the synthesis of this versatile moiety. When applied to the target compound, the photochemical step could be conducted on 15 g scale using industrially relevant [Ru(bpy)3Cl2] catalyst loadings of 0.01 mol %. This transformation is part of an overall five‐step route to the antagonist that compares favorably to the current synthetic sequence and demonstrates

  一种可见光介导的自由基Smiles 重排已被开发出来，以解决目前正在开发用于治疗抑郁症和/或肥胖。该方法能够将二氟乙醇基序直接有效地引入一系列芳基和杂芳基系统中，代表了这种多功能基团合成的新突破。当应用于目标化合物时，光化学步骤可以使用工业相关的 [Ru(bpy) 3 Cl 2 ] 催化剂负载量 0.01 mol% 以 15 g 规模进行。这种转化是拮抗剂总体五步路线的一部分，与当前的合成序列相比，并在这种特定情况下证明了光催化的明显战略优势。
• A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells
  作者：Corwin M. Nycholat、Shiteng Duan、Eva Knuplez、Charli Worth、Mila Elich、Anzhi Yao、Jeremy O’Sullivan、Ryan McBride、Yadong Wei、Steve M. Fernandes、Zhou Zhu、Ronald L. Schnaar、Bruce S. Bochner、James C. Paulson

  DOI：10.1021/jacs.9b05769

  日期：2019.9.11

  im-munoglobulin-like cell surface receptors have emerged as attractive targets for cell directed therapies due to their restricted expression on immune cells, endocytic properties and ability to modulate receptor signaling. Human Siglec-8, for instance has been identified as a therapeutic target for the treatment of eosinophil and mast cell disorders. A promising strategy to target Sig-lecs involves the

  Siglec 家族的唾液酸结合免疫球蛋白样细胞表面受体已成为细胞定向治疗的有吸引力的靶点，因为它们在免疫细胞上的表达受限、内吞特性和调节受体信号的能力。例如，人类 Siglec-8 已被确定为治疗嗜酸性粒细胞和肥大细胞疾病的治疗靶点。靶向 Sig-lecs 的一个有前景的策略涉及使用具有多价展示 Siglec 配体的脂质体纳米颗粒。这种方法的一个关键挑战是识别目标 Siglec 的高亲和力配体。在这里，我们报告了 Siglec-8 的高亲和力配体及其最接近的鼠功能直向同源物 Siglec-F 的开发，它能够将脂质体靶向表达 Siglec-8 或 -F 的细胞。筛选了 156 个合成的 9-N-磺酰基唾液酸类似物的聚糖微阵列库，以识别潜在的先导化合物。最佳配体，9-N-(2-萘基磺酰基)-Neu5Acα2-3-[6-O-磺基]-Galβ1-4GlcNAc(6'-O-磺基NSANeu5Ac)结
• [EN] UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES<br/>[FR] DERIVES DE SULFONAMIDE SUBSTITUES PAR UREE
  申请人：BIOTIE THERAPIES CORP

  公开号：WO2010146236A1

  公开（公告）日：2010-12-23

  The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially α2β1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors, their use as a medicament, e.g. for the treatment of thrombosis, inflammation, cancer and vascular diseases, pharmaceutical compositions containing them and a process for preparing them. The sulphonamide derivatives have the general formula (I) or (I').

  本发明涉及含有脲基的磺胺类衍生物。该发明还涉及将这些衍生物用作胶原受体整合素的抑制剂，特别是α2β1整合素抑制剂，例如在涉及表达胶原受体的细胞和血小板的疾病和医疗状况中使用，其用作药物，例如用于治疗血栓形成、炎症、癌症和血管疾病，含有它们的药物组合物以及制备它们的方法。这些磺胺类衍生物具有一般式(I)或(I')。
• [EN] SULFONAMIDE ANTHELMINTICS<br/>[FR] SULFONAMIDE ANTI-HELMINTHIQUE
  申请人：DU PONT

  公开号：WO2014099837A1

  公开（公告）日：2014-06-26

  Disclosed is a method for treating an animal for infection by helmintha which comprises administering to the animal a parasiticidally effective anount of a compound of Formula (1), or a pharmaceutically or veterinarily acceptable salt or a composition comprising it wherein R1, R2, R3, Q1 and J are as defined in the disclosure.

  公开了一种治疗动物寄生虫感染的方法，包括向动物投予化合物Formula（1）的寄生虫效果有效的数量，或其药用或兽医接受的盐或包含它的组合物，其中R1、R2、R3、Q1和J如披露中所定义。